Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$366.60
▲ $4.59 (+1.3%)
Market data updated: 09/18 12:42 PM
Fundamentals updated: 09/17/2026
News analyzed: 09/18/2026
Market Cap
$25.80B
Day Range
$363.14 - $368.80
52-Week Range
$223.83 - $386.00
Beta
—
Next Earnings
21.10.2026
WST is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+43.0% (1Y)
Strengths: 19/33 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Free cash flow growth
Free cash flow growth: 69.6%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $109.04 vs. price $366.60 (-70.3%)
Fair Value
Signal tension
Growth scores strong (64/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
69
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $362.01
Evidence: Euphoria score crossed 55 (now 55)
What happened after
Still awaiting outcome
1d ago · $362.01
Evidence: FOMO score jumped from 11 to 50 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
64
Quality
63
Value
33
Momentum
82
Risk
54
Sentiment
100
Fundamental
77
Institutional
0
Stocks with a similar DNA right now
SCANNING WST...
Recent media coverage on **West Pharmaceutical Services (WST)** has centered on its potential as an investment opportunity, particularly in relation to the broader **GLP-1 drug market** and its role in supporting pharmaceutical packaging solutions. Analysts have discussed its valuation gap and growth prospects amid rising demand for injectable medications. However, broader industry headlines (e.g., cybersecurity incidents, AI tools, or cell therapy advancements) do not directly involve West Pharmaceutical Services, so no additional company-specific details are available.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about West Pharmaceutical Services. News trend score: 100. Reason: 14 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
51
🎯 Conviction (vs. Emotion)
42
Psychology
57
Fundamentals
77
Technical
82
Valuation
33
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+12%
Market Narrative
86
Fundamental Reality
42
Narrative Gap
+44
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a **narrative-reality gap** (18-point divergence) where traders overvalue WST’s fundamentals (+212% DCF premium) despite weak momentum and peer underperformance. Herding dominates (45%) as traders align with peers’ relative underperformance, but euphoria (26%) and overconfidence (45%) persist due to extreme valuation disconnects. The key question is whether traders will adjust anchoring (4.3% above support) or double down on detached optimism. The absence of panic or FOMO signals a cautious, yet misaligned, collective stance.
Updated: 09/08/2026, 08:53 AM
What could change this?
👥 What the crowd believes
"Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?"
"West Pharmaceutical Services (WST) And The GLP 1 Story Behind Its Fair Value Gap"
🧠 Market Brain events driving this
📈 6D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 4/100
🗣️ Why do they disagree?
The stark divide in verdicts for WST reflects deep methodological differences in how these investors evaluate stocks. The highest-scoring approaches—Bagehot’s liquidity focus, Nelson’s cyclical positioning, and Housel’s long-term compounding lens—all see strength in stability, timing, or patient growth, suggesting resilience or favorable market conditions. Meanwhile, Graham’s strict defensive criteria and Lynch’s growth-at-a-reasonable-price filter flag the stock as too risky or overvalued, while Livermore’s trend-following rule outright rejects it. Even Fisher and Mackay, who acknowledge solid fundamentals, note crowd behavior or mediocre quality, contrasting sharply with the more optimistic cyclical or liquidity-driven perspectives. The middle ground—Marks’ mixed valuation, Schwager’s indecision, or the efficient-market skeptics—highlights uncertainty, where neither clear edge nor fundamental flaw is decisive.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 84
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 77
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 73
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 66
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 62
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 47
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 33
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 31
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 30
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 29
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 26
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 20
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 4
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A pattern consistent with an early/mid distribution phase — a trading range after an advance with declining volume.
Medium confidence
$325.27
Range Bottom
$386.00
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
35.9%
Operating Margin
19.0%
Net Margin
16.1%
EBITDA Margin
24.6%
ROE
15.5%
ROA
11.6%
ROIC
—
EPS
$6.83
Cash
$791.30M
Total Debt
$202.80M
Current Ratio
3.02
Debt/Equity
0.06
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 29.7.2026 | $0.220 |
| 28.7.2026 | $0.220 |
| 29.4.2026 | $0.220 |
| 28.4.2026 | $0.220 |
| 28.1.2026 | $0.220 |
| 27.1.2026 | $0.220 |
| 12.11.2025 | $0.220 |
| 11.11.2025 | $0.220 |
| 30.7.2025 | $0.210 |
| 29.7.2025 | $0.210 |
| 30.4.2025 | $0.210 |
| 29.4.2025 | $0.210 |
How is Fair Value calculated? →
Current Price
$366.60
Estimated Fair Value (DCF)
$109.04
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-70.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
2.2%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 2.2% | $479.08M | $439.52M |
| 2 | 2.3% | $489.87M | $412.32M |
| 3 | 2.3% | $501.31M | $387.11M |
| 4 | 2.4% | $513.43M | $363.73M |
| 5 | 2.5% | $526.27M | $342.04M |
Base FCF (last actual year)
$468.90M
Terminal Value
$8.30B
Present Value of Terminal Value
$5.39B
Enterprise Value
$7.34B
Net Debt
$-588.50M
Equity Value
$7.93B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$43.69
Tangible Book Value per Share (Tangible NAV)
$42.07
Sentiment based on basic keywords (not AI) — 14 positive, 5 neutral, 1 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 14.9.2026
SeekingAlpha · 13.9.2026
Yahoo · 11.9.2026
Zacks · 11.9.2026
Yahoo · 11.9.2026
Zacks · 11.9.2026
Yahoo · 10.9.2026
Zacks · 10.9.2026
Yahoo · 10.9.2026
Zacks · 10.9.2026
West Pharmaceutical Services (WST) currently has a StockIQ AI score of 69/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
WST currently scores 69/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, WST's estimated fair value is $109.04, which is 70.3% below the current price of $366.60. This is one valuation model among several signals in the fair-value category, not a price target.
WST's technical score is 82/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Free cash flow growth: 69.6%; Operating margin is stable or improving over time; Debt/equity: 0.06.
Based on the real signals StockIQ computed: Estimated fair value: $109.04 vs. price $366.60 (-70.3%); Calmar: -0.04 (3y annualized return -2.4% / max drawdown 53.9%); P/E: 54.1.
Yes — WST has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 3 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Lagarde Michel | Grant/Award from Employer | 8.9.2026 | 12,088 | +12,088 | — |
| Lagarde Michel | Grant/Award from Employer | 8.9.2026 | 13,879 | +13,879 | — |
| Lagarde Michel | Grant/Award from Employer | 8.9.2026 | 6,200 | +6,200 | — |
| Favorite Annette F | Exercise of Derivative Securities | 8.9.2026 | 2,500 | -2,500 | — |
| Lagarde Michel | Grant/Award from Employer | 8.9.2026 | 3,600 | +3,600 | — |
| Favorite Annette F | Open Market Sale | 8.9.2026 | 2,818 | -2,818 | $340.81 |
| Lagarde Michel | Grant/Award from Employer | 8.9.2026 | 4,950 | +4,950 | — |
| Favorite Annette F | Exercise of Derivative Securities | 8.9.2026 | 2,817 | -2,817 | — |
| Favorite Annette F | Open Market Sale | 8.9.2026 | 2,817 | -2,817 | $340.81 |
| Favorite Annette F | Exercise of Derivative Securities | 8.9.2026 | 2,818 | -2,818 | — |
| Lagarde Michel | Grant/Award from Employer | 8.9.2026 | 11,081 | +11,081 | — |
| Favorite Annette F | Exercise of Derivative Securities | 8.9.2026 | 2,500 | +2,500 | $89.64 |
| Favorite Annette F | Exercise of Derivative Securities | 8.9.2026 | 2,818 | +2,818 | $83.47 |
| Favorite Annette F | Exercise of Derivative Securities | 8.9.2026 | 2,817 | +2,817 | $83.47 |
| Favorite Annette F | Open Market Sale | 8.9.2026 | 2,500 | -2,500 | $340.81 |
| McMahon Robert W. | Exercise of Derivative Securities | 11.8.2026 | 794.469 | +794.469 | — |
| McMahon Robert W. | Exercise of Derivative Securities | 11.8.2026 | 6,354.736 | -6,354.736 | — |
| McMahon Robert W. | Tax Withholding in Shares | 11.8.2026 | 345.515 | -345.515 | $351.37 |
| McMahon Robert W. | Exercise of Derivative Securities | 11.8.2026 | 6,354.736 | +6,354.736 | — |
| McMahon Robert W. | Tax Withholding in Shares | 11.8.2026 | 2,763.675 | -2,763.675 | $351.37 |
| McMahon Robert W. | Exercise of Derivative Securities | 11.8.2026 | 794.469 | -794.469 | — |
| HAUGEN JANET BRUTSCHEA | Grant/Award from Employer | 30.6.2026 | 46 | +46 | $359.00 |
| HAUGEN JANET BRUTSCHEA | Grant/Award from Employer | 30.6.2026 | 307 | +46 | $359.00 |
| Campbell Shane Alden | Exercise of Derivative Securities | 12.5.2026 | 295.995 | -295.995 | — |
| Campbell Shane Alden | Exercise of Derivative Securities | 12.5.2026 | 295.995 | +295.995 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,195,650 shares short as of 2026-08-31 · vs. 2,510,898 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
58.1% of trading volume this week was short selling, vs. 53.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology